Table 1. Effects of GEF and SAL as single agents in colorectal cancer and epithelial cell lines.
| Cell line | EGFR mutation | KRAS mutation (Codon 12WT = GGC) | KRAS mutation (Codon 13WT = GGC) | CCK8 analysis | Colony formation | ||
|---|---|---|---|---|---|---|---|
| GEF IC50 (μM) | SAL IC50 (μM) | GEF IC50 (μM) | SAL IC50 (μM) | ||||
| SW1116 | WT | WT | WT | 4.1 | 12.5 | 2.6 | 10.9 |
| LOVO | WT | WT | GAC | 6.9 | 18.7 | 5.4 | 22.3 |
| HCT-116 | WT | WT | GAC | 31.7 | 25.5 | 12.9 | 28.4 |
| SW480 | WT | GTT | WT | 6.2 | 21.3 | 3.8 | 16.5 |
| HT-29 | WT | WT | WT | 3.5 | 15.8 | 1.9 | 12.6 |
| NCM460 | WT | WT | WT | 12.8 | 17.7 | 6.9 | 10.6 |
Cell growth inhibitory effects of salinomycin (SAL) and gefitinib (GEF) given as single agents were evaluated by CCK8 analysis and colony formation assay. IC50 values for each drug were calculated by performing dose–response experiments. For CCK8 analysis, cells were treated for 48 h with SAL (0.5–100 μM) and GEF (0.1–50 μM). For colony formation assay, cells were treated for 24 h with SAL (0.5–100 μM) and GEF (0.1–50 μM), after media removal, cells were cultured with fresh medium for additional 15 days. Experiments were performed in triplicate.